Brad Robling

VP Lilly New Ventures at Eli Lilly and Company

Speaker

Brad Robling is the Global Head Lilly Ventures - Investing. Brad co-heads the Lilly Ventures team globally focusing primarily on investing / strategy for the venture fund and equity portfolio. Prior to joining the Eli Lilly venture team, he held positions in business development and investor relations. Prior to Lilly, he held business development / finance positions in business development for a global 100 technology company and two startup companies in the Bay Area. He also spent over 10 years at financial / consulting companies: Deloitte Consulting and Ernst and Young.

Brad currently serves on the boards of Sitryx Therapeutics based in Oxford, UK, Auron Therapeutics based in Wellesley, MA and Therini Bio based in San Francisco.